These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 12670298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The place of pegvisomant in the management of acromegaly.
    Parkinson C, Trainer PJ.
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 6. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S, Gaspo R, Serri O, Ur E, Chik CL.
    Clin Invest Med; 2009 Dec 01; 32(6):E265. PubMed ID: 20003832
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H.
    J Clin Endocrinol Metab; 2005 Oct 01; 90(10):5627-31. PubMed ID: 16046586
    [Abstract] [Full Text] [Related]

  • 10. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
    Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ.
    Clin Endocrinol (Oxf); 2003 Aug 01; 59(2):168-74. PubMed ID: 12864793
    [Abstract] [Full Text] [Related]

  • 11. The German ACROSTUDY: past and present.
    Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study.
    Eur J Endocrinol; 2009 Nov 01; 161 Suppl 1():S3-S10. PubMed ID: 19684061
    [Abstract] [Full Text] [Related]

  • 12. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I.
    Eur J Endocrinol; 2009 Apr 01; 160(4):535-42. PubMed ID: 19147599
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
    van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO.
    Lancet; 2001 Nov 24; 358(9295):1754-9. PubMed ID: 11734231
    [Abstract] [Full Text] [Related]

  • 14. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
    Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators.
    Eur J Endocrinol; 2007 Jan 24; 156(1):75-82. PubMed ID: 17218728
    [Abstract] [Full Text] [Related]

  • 15. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ.
    Eur J Endocrinol; 2005 Jan 24; 152(1):47-51. PubMed ID: 15762186
    [Abstract] [Full Text] [Related]

  • 16. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
    Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML.
    J Clin Endocrinol Metab; 2005 Oct 24; 90(10):5684-91. PubMed ID: 16076947
    [Abstract] [Full Text] [Related]

  • 17. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
    Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ.
    Eur J Endocrinol; 2001 Oct 24; 145(4):451-6. PubMed ID: 11581004
    [Abstract] [Full Text] [Related]

  • 18. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
    Jehle S, Reyes CM, Sundeen RE, Freda PU.
    J Clin Endocrinol Metab; 2005 Mar 24; 90(3):1588-93. PubMed ID: 15585549
    [Abstract] [Full Text] [Related]

  • 19. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ.
    J Clin Endocrinol Metab; 2012 Apr 24; 97(4):1187-93. PubMed ID: 22278424
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A.
    J Clin Endocrinol Metab; 2002 Apr 24; 87(4):1692-9. PubMed ID: 11932303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.